logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
O

Oncology R&D, Astrazeneca

Scholars2
Papers2
Citations0
Related Papers (2)
Publication Date
delete
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer
errEuropean Urology Oncology
IF9.3
err2025-11-04
err0
errOAAI
errFred Saad; Andrew J. Armstrong; Mototsugu Oya; Neal Shore; Giuseppe Procopio; João Daniel Guedes; Cagatay Arslan; Niven Mehra; Emma Brown; Jae Young Joung; Mikio Sugimoto; Oliver Sartor; Christian Poehlein; Elizabeth A. Harrington; Jinyu Kang; Noel Clarke
errShare
errSave
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
errAnnals of Oncology
IF65.4
err2025-10-21
err0
errOAAI
errNadia Harbeck; Shanu Modi; Lajos Pusztai; Shinji Ohno; Jiong Wu; Sung-Bae Kim; Atsushi Yoshida; Alessandra Fabi; Xuchen Cao; Rona Joseph; Rubi Li; Bogdan Żurawski; Santiago Escrivá-de-Romaní; Renata Meneguetti; Archara Supavavej; Shin-Cheh Chen; Zhenzhen Liu; Catherine Kelly; Giuseppe Curigliano; William F. Symmans; Mohammad Gufran; Jun Ke; Adam Konpa; Pia Herbolsheimer; Jean-François Boileau
errShare
errSave